EP1283053A1 - Inhibitors of HER3 activity - Google Patents

Inhibitors of HER3 activity Download PDF

Info

Publication number
EP1283053A1
EP1283053A1 EP01119260A EP01119260A EP1283053A1 EP 1283053 A1 EP1283053 A1 EP 1283053A1 EP 01119260 A EP01119260 A EP 01119260A EP 01119260 A EP01119260 A EP 01119260A EP 1283053 A1 EP1283053 A1 EP 1283053A1
Authority
EP
European Patent Office
Prior art keywords
her3
antibody
composition
inhibitor
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01119260A
Other languages
German (de)
English (en)
French (fr)
Inventor
Axel Dr. Ullrich
Edward Htun-Van Der Horst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Original Assignee
Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8178284&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1283053(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Max Planck Gesellschaft zur Foerderung der Wissenschaften eV filed Critical Max Planck Gesellschaft zur Foerderung der Wissenschaften eV
Priority to EP01119260A priority Critical patent/EP1283053A1/en
Priority to CN028156153A priority patent/CN1541109B/zh
Priority to EP09002792A priority patent/EP2067792A2/en
Priority to CN2010105512370A priority patent/CN102078613A/zh
Priority to PT02794590T priority patent/PT1414494E/pt
Priority to ES02794590T priority patent/ES2323772T3/es
Priority to PCT/EP2002/008938 priority patent/WO2003013602A1/en
Priority to EP02794590A priority patent/EP1414494B1/en
Priority to AU2002333384A priority patent/AU2002333384B2/en
Priority to CA2456723A priority patent/CA2456723C/en
Priority to US10/486,113 priority patent/US9011851B2/en
Priority to DE60231407T priority patent/DE60231407D1/de
Priority to JP2003518606A priority patent/JP5226926B2/ja
Priority to DK02794590T priority patent/DK1414494T3/da
Priority to AT02794590T priority patent/ATE424219T1/de
Publication of EP1283053A1 publication Critical patent/EP1283053A1/en
Priority to CY20091100593T priority patent/CY1110322T1/el
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals

Definitions

  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as an active agent an inhibitor of HER3 activity, particularly an anti-HER3-antibody. Further, the use of this composition for the diagnosis, prevention or treatment of hyperproliferative diseases, particularly tumor diseases is disclosed.
  • Protein tyrosine kinases are known to be enzymes, which mediate signal transduction processes that regulate cell growth and differentiation. Receptor protein tyrosine kinases act via ligand-stimulated tyrosine phosphorylation of substrates.
  • HER3 also called ErbB3 is a member of the epidermal growth factor receptor (EGFR) subfamily of receptor protein tyrosine kinases (Plowman et al., Proc. Natl. Acad. Sci. U.S.A. 87 (1990), 4905-4909; Kraus et al., Proc. Natl. Acad. Sci. U.S.A. 86 (1989), 9193-9197 and Kraus et al., Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 2900-2904).
  • EGFR epidermal growth factor receptor
  • HER3 has been found to be overexpressed in several types of cancer such as breast, gastrointestinal and pancreatic cancers.
  • HER3 is co-expressed with HER2
  • HER2 another member of the EGFR subfamily of receptor protein tyrosine kinases, an active heterodimeric signalling complex is formed.
  • Herceptin an agonistic monoclonal antibody against HER2 with an anti-HER3-antibody ( ⁇ -HER3-ECD) (murine monoclonal antibody IgG1, Upstate Biotechnology, Cat.No.# 05-471), directed against the Heregulin binding site of HER3 in invasive breast cancer cell lines MCR-7 (DKFZ Heidelberg), MDA-MB-468 (ATCC HTB-132) and MDA-MB231 (ATCC HTB-26) expressing different HER2:HER3 ratios.
  • ⁇ -HER3-ECD murine monoclonal antibody IgG1, Upstate Biotechnology, Cat.No.# 05-471
  • ⁇ -HER3-ECD prior to ⁇ / ⁇ -Heregulin ( ⁇ / ⁇ -HRG) stimulation diminished the HER2/HER3 tyrosine phosphorylation content in contrast to Herceptin.
  • ⁇ -HER3-ECD abrogated HER2/HER3 heterodimerization and also reduced the complex formation of the p85 subunit of PI 3 -kinase and the adaptor protein SHC with HER3, resulting in decreased PI 3 -kinase and c-jun-terminal kinase activity (JNK), respectively.
  • ⁇ -HER3-ECD was also capable of downregulating extracellular signal-regulated kinase 2 (ERK2) after ⁇ / ⁇ -HRG stimulation. Furthermore, we demonstrate a significant reduction of the migratory and proliferative property of the breast cancer cell lines after pretreatment with ⁇ -HER3-ECD. These results were confirmed with murine monoclonal antibodies generated in our laboratory by immunizing Balb/c mice with the extracellular part of HER3. Our data clearly show that ⁇ -HER3-ECD is more potent in diminishing signal transduction processes after HRG stimulation than Herceptin. These data demonstrate the great potential of anti-HER3 antibodies or other inhibitory agents for the therapy of breast cancer and other malignancies characterized by hypersignalling through HER3 and its heterodimerization partners.
  • ERK2 extracellular signal-regulated kinase 2
  • the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising as an active agent a specific type of inhibitor of HER3 activity and pharmaceutically acceptable carriers, diluents and/or adjuvants.
  • the HER3 inhibitor of the invention is characterized in that binding of the inhibitor to HER3 reduces HER3 mediated signal transduction.
  • a reduction of HER3 mediated signal transduction may be caused by a downregulation of HER3 resulting in an at least partial disappearance of HER3 molecules from the cell surface.
  • the reduction of HER3 mediated signal transduction may be caused by a stabilization of HER3 on the cell surface in a substantially inactive form, i.e. a form which exhibits a lower signal transduction compared to the non-stabilized form.
  • the inhibitor of the invention may influence the binding of Heregulin to HER3, particularly by decreasing the binding of Heregulin to HER3, it preferably does not compete with the binding of Heregulin to HER3.
  • the inhibitor is an anti-HER3-antibody.
  • the antibody is directed against the extracellular domain of HER3. It should be noted, however, that also other HER3 inhibitors, particularly low molecular weight inhibitors may be used.
  • antibody covers monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g. bispecific antibodies) formed from at least two antibodies and antibody fragments as long as they exhibit the desired activity.
  • the antibody may be a monoclonal antibody which may be obtained by the hybridoma method as described by Köhler et al. (Nature 256 (1975), 495) or by recombinant DNA methods (cf. e.g. U.S.Patent 4,816,567). Monoclonal antibodies may also be isolated from phage antibody libraries using techniques described in Clackson et al. (Nature 352 (1991), 624-628) and Marks et al. (J.Mol.Biol.222 (1991), 581-597).
  • the antibody may be an IgM, IgG, e.g. IgG1, IgG2, IgG3 or IgG4.
  • Antibody fragments comprise a portion of an antibody, generally the antigen binding or variable region of the intact antibody.
  • Examples of antibody fragments include Fab, Fab', F(ab') 2 and Fv fragments, diabodies, single chain antibody molecules and multispecific antibody fragments.
  • the antibody may be a recombinant antibody or antibody fragment, more particularly chimeric antibodies or fragments thereof (Morrison et al., Proc. Natl. Acad. Sci. U.S.A. 81 (1984), 6851-6855) or humanized antibodies (Jones et al., Nature 321 (1986), 522-525; Reichmann et al., Nature 332 (1988), 323-329 and Presta, Curr. Op. Struct. Biol. 2 (1992), 593-596) or single chain Fv antibodies (Plücktuhn in: The Pharmacology of Monoclonal Antibodies 113, Rosenburg and Moore, EDS, Springer Verlag, N.Y. (1994), pp. 269-315) and diabodies (Hollinger et al., Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 6444-6448).
  • chimeric antibodies or fragments thereof or humanized antibodies
  • humanized antibodies Jone
  • the antibody is selected from antibodies 1 B4C3 (IgG2a) and 2D1 D12 (IgG1) produced by the hybridoma cell lines DSM... or DSM ACC 2517, fragments thereof or recombinant derivatives thereof.
  • 1B4C3 is an antibody which leads to internalization of HER3
  • 2D1D12 is an antibody which leads to stabilization of HER3.
  • antibodies which have substantially the same biological activity e.g. as described in the Examples
  • compared to the antibodies produced by the deposited hybridoma cell lines for example, by binding to the same epitope on HER3.
  • the hybridoma cell line DSM ACC 2517 was deposited under the Budapest Treaty for the Deposit of Microorganisms on July 24, 2001 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, 38124 Braunschweig, Germany.
  • the hybridoma cell line producing the antibody 1B4C3 was deposited on August 07, 2001 at DSMZ.
  • the antibody of the invention may be coupled to a labelling group, particularly for diagnostic applications.
  • suitable labelling groups such as radioactive groups, fluorescent groups or other labelling groups are known in the art.
  • the antibody may be coupled to an effector group, e.g. a cytotoxic group such as a radioactive group, a toxin or another effector group as known in the art.
  • the present application relates to the use of an inhibitor of HER3 activity, wherein binding of said inhibitor to HER3 reduces HER3 mediated signal transduction, for the manufacture of an agent for the diagnosis, prevention and/or treament of hyperproliferative diseases, particularly tumor diseases such as breast cancer, melanoma or tumor or formation of tumor metastasis.
  • the disease may be associated with increased HER3 signal transduction and may be associated with concomittant HER2 expression or lack of HER2 expression.
  • the disease is associated with increased HER3 phosphorylation, increased HER2/HER3 heterodimerization and/or increased PI 3 kinase and/or c-jun terminal kinase activity.
  • the HER3 inhibitor of the invention particularly an anti-HER3-antibody, shows a significantly higher efficiency in diminishing signal transduction processes than a HER2 inhibitor such as Herceptin.
  • the invention relates to a method for diangosing, preventing or treating a hyperproliferative disease, particulary a tumor disease, comprising administering a subject in need thereof, e.g. a human, an effective amount of an inhibitor of HER3 activity, wherein binding of said inhibitor to HER3 reduces HER3 mediated signal transduction.
  • the HER3 inhibitor particularly the anti-HER3-antibody may be formulated by mixing the active agent with physiologically acceptable carriers, diluents and/or adjuvants, e.g. in the form of lyophilized formulations, aqueous solutions, dispersions or solid preparations such as tablets, dragees or capsules as described in Remington's Pharmaceutical Sciences.
  • the formulation may also contain more than one active compound, e.g. inhibitors of other receptor protein tyrosine kinases such as EGFR, HER2, HER4 or vascular endothelial factor (VEGF).
  • the composition may comprise a cytotoxic agent or a cytokine.
  • the inhibitor of the invention is also suitable for diagostic applications, e.g. in order to determine the expression and/or activity of HER3 on target cells. Such a diagnostic application may be carried out according to known procedures.
  • ⁇ g/kg to 15 mg/kg of antibody may be administered to a human patient, e.g. by one or more separate administrations or by continuous infusion.
  • a typical daily dosage might range from about 1 ⁇ g/kg to about 100 mg/kg or more, depending on the factors mentioned above.
  • the treatment is sustained until a desired suppression of disease symptoms occurs.
  • Monoclonal antibody ⁇ -HER3 ECD decreases receptor tyrosine phosphorylation of HER3 and HER2
  • MCF-7 (DKFZ - Heidelberg), MDA-MB-468 (ATCC HTB-132) and MDA-MB-231 (ATCC HTB-26) were chosen on the basis of their different ratios of HER2:HER3 and their inherent migratory properties with MDA-MB-231 being the most invasive cell line.
  • HRG Heregulin
  • PY anti-phosphotyrosine antibody
  • ⁇ -HER3 ECD abrogates association of SHC and PI 3 -K with HER3 and of GRB2 with HER2
  • ⁇ -HER3 ECD has an effect on the known substrates of HER3, namely SHC and phosphatidyl-3-OH-kinase (PI 3 -K), which are effector proteins responsible for MAPK cascade activation and lipid signalling, respectively. Therefore, we immunoprecipitated SHC and PI 3 -K under the experimental conditions described above and assessed the tyrosine phosphorylation of these effectors. As shown in Figure 2, ⁇ -HER3 ECD significantly descreased the tyrosine phosphorylation of SHC in the cell lines MCF-7 and MDA-MB-486 ( Figure 2a, b compare lane 13 with 16).
  • the adaptor protein SHC mediates MAPK signalling pathways downstream of growth-factor receptors, activating ERK2 and JNK, resepectively.
  • MAPK kinase assays under the same experimental conditions in MCF-7 and MB-468 ( Figure 3).
  • ERK2 activity was only slightly but significantly decreased through ⁇ -HER3 ECD , whereas HC had no effect on ERK2 activity (data not shown).
  • ⁇ -HER3 ECD enhances endocytotic downregulation of HER3
  • HER2 and HER3 are endocytosed and recycled after HRG stimulation.
  • HER3 was then immunoprecipitated after biotinylation of the membrane proteins.
  • HER3 is endocytosed rapidly after pretreatment with ⁇ -HER3 ECD ( Figure 4b upper panel).
  • ⁇ -HER3 ECD inhibits migratory and proliferative properties of breast cancer cell lines
  • Immunization was performed by intraperitoneal injection with 22 ⁇ g of HER3-6xHis-CT according to the manufacturer's protocol (Qiagen ImmunEasy Mouse Adjuvant). Hybridoma cell lines producing monoclonal antibodies were generated using standard methods.
  • Monoclonal antibodies 1B4C3 and 2D1D12 inhibit downstream signals of HER3 and HER2
  • Monoclonal antibody 2D1D12 inhibits proliferation of breast cancer cell lines MDA-MB-435S, ZR-75-1 and melanoma cell line Mel Gerlach
  • hybridoma cell lines producing antibodies 1B4C3 and 2C1D12 were deposited on August 07, 2001 and July 24, 2001, respectively, at DSMZ.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01119260A 2001-08-09 2001-08-09 Inhibitors of HER3 activity Withdrawn EP1283053A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP01119260A EP1283053A1 (en) 2001-08-09 2001-08-09 Inhibitors of HER3 activity
AT02794590T ATE424219T1 (de) 2001-08-09 2002-08-09 Hemmende antikörper der her3-aktivität
AU2002333384A AU2002333384B2 (en) 2001-08-09 2002-08-09 Inhibitors of HER3 activity
US10/486,113 US9011851B2 (en) 2001-08-09 2002-08-09 Inhibitors of her3 activity
CN2010105512370A CN102078613A (zh) 2001-08-09 2002-08-09 Her3活性抑制剂
PT02794590T PT1414494E (pt) 2001-08-09 2002-08-09 Anticorpos inibidores da actividade de her3
ES02794590T ES2323772T3 (es) 2001-08-09 2002-08-09 Anticuerpos inhibidores de la actividad de her3.
PCT/EP2002/008938 WO2003013602A1 (en) 2001-08-09 2002-08-09 Inhibitors of her3 activity
EP02794590A EP1414494B1 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of her3 activity
CN028156153A CN1541109B (zh) 2001-08-09 2002-08-09 Her3活性抑制剂
CA2456723A CA2456723C (en) 2001-08-09 2002-08-09 Inhibitors of her3 activity
EP09002792A EP2067792A2 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of HER3 activity
DE60231407T DE60231407D1 (de) 2001-08-09 2002-08-09 Hemmende antikörper der her3-aktivität
JP2003518606A JP5226926B2 (ja) 2001-08-09 2002-08-09 Ｈｅｒ３活性の阻害剤
DK02794590T DK1414494T3 (da) 2001-08-09 2002-08-09 Hæmmende antistoffer af HER3-aktivitet
CY20091100593T CY1110322T1 (el) 2001-08-09 2009-06-03 Αναστολεις της her3 δραστικοτητας

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01119260A EP1283053A1 (en) 2001-08-09 2001-08-09 Inhibitors of HER3 activity

Publications (1)

Publication Number Publication Date
EP1283053A1 true EP1283053A1 (en) 2003-02-12

Family

ID=8178284

Family Applications (3)

Application Number Title Priority Date Filing Date
EP01119260A Withdrawn EP1283053A1 (en) 2001-08-09 2001-08-09 Inhibitors of HER3 activity
EP02794590A Revoked EP1414494B1 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of her3 activity
EP09002792A Withdrawn EP2067792A2 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of HER3 activity

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP02794590A Revoked EP1414494B1 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of her3 activity
EP09002792A Withdrawn EP2067792A2 (en) 2001-08-09 2002-08-09 Inhibitory antibodies of HER3 activity

Country Status (13)

Country Link
US (1) US9011851B2 (https=)
EP (3) EP1283053A1 (https=)
JP (1) JP5226926B2 (https=)
CN (2) CN1541109B (https=)
AT (1) ATE424219T1 (https=)
AU (1) AU2002333384B2 (https=)
CA (1) CA2456723C (https=)
CY (1) CY1110322T1 (https=)
DE (1) DE60231407D1 (https=)
DK (1) DK1414494T3 (https=)
ES (1) ES2323772T3 (https=)
PT (1) PT1414494E (https=)
WO (1) WO2003013602A1 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
WO2009156179A1 (en) * 2008-06-27 2009-12-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Her3 as a determinant for the prognosis of melanoma
WO2013071058A1 (en) * 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
EP2611829A4 (en) * 2010-09-03 2014-05-07 Glaxosmithkline Ip Dev Ltd NOVEL ANTIGEN BINDING PROTEINS
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US9688761B2 (en) 2013-12-27 2017-06-27 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
EP2400021B1 (en) * 2002-03-26 2016-11-30 Zensun (Shanghai) Science & Technology, Co., Ltd. ErbB3 based methods and compositions for treating neoplasms
TWI229650B (en) * 2002-11-19 2005-03-21 Sharp Kk Substrate accommodating tray
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
JP5656406B2 (ja) * 2006-11-28 2015-01-21 ユースリー ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングＵ３ Ｐｈａｒｍａ ＧｍｂＨ 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３
CA2683559C (en) 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
ES2526211T3 (es) * 2007-07-13 2015-01-08 Nestec S.A. Selección de fármacos para la terapia del cáncer de pulmón utilizando matrices basadas en anticuerpos
US8470542B2 (en) 2008-12-01 2013-06-25 Laboratory Corporation Of America Holdings Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
SG172983A1 (en) 2009-01-15 2011-08-29 Lab Corp America Holdings Methods of determining patient response by measurement of her-3
WO2010085845A1 (en) * 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
CN104447995A (zh) * 2009-03-20 2015-03-25 霍夫曼-拉罗奇有限公司 双特异性抗-her抗体
AU2010242914B2 (en) * 2009-04-29 2014-11-13 Trellis Bioscience, Llc Improved antibodies immunoreactive with heregulin-coupled HER3
MX358013B (es) 2009-11-13 2018-08-01 Amgen Inc Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
MA33892B1 (fr) * 2009-12-22 2013-01-02 Roche Glycart Ag Anticorps anti-her3, et leurs utilisations
CN102884085B (zh) 2010-04-09 2016-08-03 Aveo制药公司 抗erbb3抗体
EP2590654B1 (en) 2010-07-09 2016-12-21 Exelixis, Inc. Combinations of kinase inhibitors for the treatment of cancer
NZ607337A (en) 2010-08-20 2015-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (her3)
JP6033783B2 (ja) 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US20140134170A1 (en) 2011-03-11 2014-05-15 Merrimack Pharmaceuticals, Inc. Use of inhibitors of egfr-family receptors in the treatment of hormone refractory breast cancers
SG192775A1 (en) 2011-03-15 2013-09-30 Merrimack Pharmaceuticals Inc Overcoming resistance to erbb pathway inhibitors
CN105884900A (zh) 2011-04-19 2016-08-24 梅里麦克制药股份有限公司 单特异性和双特异性抗igf-1r和抗erbb3抗体
NO2707391T3 (https=) 2011-05-13 2018-04-07
KR102101806B1 (ko) * 2011-05-19 2020-04-20 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 항-인간-her3 항체 및 이의 용도
AU2012274461A1 (en) 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
HK1200468A1 (en) 2011-09-30 2015-08-07 Regeneron Pharmaceuticals, Inc. Anti-erbb3 antibodies and uses thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
JP6180425B2 (ja) * 2011-11-23 2017-08-23 メディミューン，エルエルシー Ｈｅｒ３に特異的な結合分子及びそれらの使用
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
ES2842201T3 (es) 2012-02-23 2021-07-13 Daiichi Sankyo Europe Gmbh Inhibidor de HER3 para modulación de radiosensibilidad
US9725511B2 (en) 2012-11-08 2017-08-08 Hoffmann-La Roche Inc. Anti-HER3/HER4 antibodies binding to the beta-hairpin of HER3 and the beta-hairpin of HER4
MX2015005757A (es) 2012-11-08 2015-11-18 Hoffmann La Roche Proteinas ligantes de antigeno her3 de union a la horquilla beta de her3.
CN113201073A (zh) 2012-11-21 2021-08-03 詹森生物科技公司 双特异性EGFR/c-Met抗体
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
US20170275367A1 (en) 2012-11-21 2017-09-28 Janssen Biotech, Inc. Bispecific EGFR/C-Met Antibodies
US9180185B2 (en) 2013-01-11 2015-11-10 Hoffman-La Roche Inc. Combination therapy of anti-HER3 antibodies
CN105209493B (zh) * 2013-03-14 2019-05-03 德克萨斯州大学系统董事会 用于诊断和治疗用途的her3特异性单克隆抗体
WO2014165855A1 (en) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
EP2821071A1 (en) 2013-07-04 2015-01-07 Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) Compounds for breast cancer treatment
US11305012B2 (en) 2013-09-24 2022-04-19 Medimmune, Llc Binding molecules specific for HER3 and uses thereof
CN105899226B (zh) 2013-10-14 2020-05-12 詹森生物科技公司 半胱氨酸工程化iii型纤连蛋白域结合分子
WO2015066543A1 (en) * 2013-11-01 2015-05-07 Board Of Regents, The University Of Texas System Targeting her2 and her3 with bispecific antibodies in cancerous cells
KR102399277B1 (ko) 2014-04-10 2022-05-18 다이이찌 산쿄 가부시키가이샤 항her3 항체-약물 콘주게이트
US10745490B2 (en) 2014-04-11 2020-08-18 Celldex Therapeutics, Inc. Anti-ErbB antibodies and methods of use thereof
MX2016014416A (es) 2014-05-14 2017-02-23 Hoffmann La Roche Anticuerpos anti-her3 que se unen a la horquilla beta de her3.
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
EP4180455A1 (en) 2015-06-29 2023-05-17 Daiichi Sankyo Company, Limited Method for selectively manufacturing antibody-drug conjugate
CR20180177A (es) 2015-09-30 2018-06-22 Janssen Biotech Inc Anticuerpos agonistas que se unen específicamente a cd40 humana y método de uso
JP2019527540A (ja) 2016-06-21 2019-10-03 ヤンセン バイオテツク，インコーポレーテツド システイン操作フィブロネクチンｉｉｉ型ドメイン結合分子
BR112019011794A2 (pt) 2016-12-12 2019-10-29 Daiichi Sankyo Co Ltd composição farmacêutica, e, método terapêutico.
NZ754187A (en) 2016-12-14 2026-02-27 Janssen Biotech Inc Cd8a-binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
CA3050668C (en) 2017-01-17 2023-08-15 Daiichi Sankyo Company, Limited Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
JP2020510673A (ja) 2017-03-03 2020-04-09 ヤンセン バイオテツク，インコーポレーテツド がんの治療のための低分子ｃｓｆ−１ｒ阻害剤とｃｄ４０に特異的に結合するアゴニスト抗体とを含む併用療法
TW202532102A (zh) 2017-05-15 2025-08-16 日商第一三共股份有限公司 抗體－藥物結合物及其用途
BR112020003466B1 (pt) 2017-08-31 2023-12-12 Daiichi Sankyo Company, Limited Métodos de produção de composto, e, composto
ES3057444T3 (en) 2017-08-31 2026-03-02 Daiichi Sankyo Co Ltd Improved method for producing antibody-drug conjugate
HUE067382T2 (hu) 2018-05-18 2024-10-28 Daiichi Sankyo Co Ltd Anti-MUC1-exatecan antitest-hatóanyag konjugátum
TWI846717B (zh) 2018-07-27 2024-07-01 日商第一三共股份有限公司 辨識抗體-藥物結合物之藥物部位的蛋白質
TW202537643A (zh) 2018-07-31 2025-10-01 日商第一三共股份有限公司 抗體-藥物結合物之用途
GB201913079D0 (en) * 2019-09-11 2019-10-23 Hummingbird Bioscience Holdings Pte Ltd Treatment and prevention of cancer using her3 antigen-binding molecules
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
AU2022293634A1 (en) * 2021-06-15 2024-01-18 Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
WO1997035885A1 (en) * 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2000078347A1 (en) * 1999-06-18 2000-12-28 The Victor Chang Cardiac Research Institute Limited Cell growth inhibition
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CA2037440A1 (en) 1990-03-02 1991-09-03 Gregory D. Plowman Her3: a novel egf receptor homolog
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
WO1998002540A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Chimeric heteromultimer adhesins
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
EP1228766A1 (en) 2001-01-31 2002-08-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. PYK2 phosphorylation by HER3 induces tumor invasion
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5480968A (en) * 1989-12-01 1996-01-02 The United States Of America As Represented By The Department Of Health And Human Services Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto
US5804396A (en) * 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
WO1997035885A1 (en) * 1996-03-27 1997-10-02 Genentech, Inc. ErbB3 ANTIBODIES
WO2000031048A1 (en) * 1998-11-19 2000-06-02 Warner-Lambert Company N-[4-(3-chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide, an irreversible inhibitor of tyrosine kinases
WO2000078347A1 (en) * 1999-06-18 2000-12-28 The Victor Chang Cardiac Research Institute Limited Cell growth inhibition
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
D. BAECKSTRÖM ET AL.: "Morphogenetic and proliferative responses to heregulin of mammary epithelial cells in vitro are dependent on HER2 and HER3 and differ from the responses to HER2 homodimerisation or hepatocyte growth factor.", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 16, no. 6, June 2000 (2000-06-01), Greece, pages 1081 - 1090, XP001030626 *
D. TODD ET AL.: "Ionizing radiation stimulates existing signal transduction pathways involving the activation of epidermal growth factor receptor ans erbB-3, and changes of intracellular calcium in A431 human squamous carcinoma cells.", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH, vol. 19, no. 6, November 1999 (1999-11-01), USA, pages 885 - 908, XP001030590 *
R. VADLAMUDI ET AL.: "Regulation of cyclooxygenase-2 pathway by HER2 receptor.", ONCOGENE, vol. 18, no. 2, 14 January 1999 (1999-01-14), Basingstoke, GB, pages 305 - 314, XP001030629 *
T. RAJKUMAR ET AL.: "A monoclonal antibody to the human c-erbB3 protein stimulates the anchorage-independent growth of breast cancer cell lines.", BRITISH JOURNAL OF CANCER, vol. 70, 1994, GB, pages 459 - 465, XP000676619 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647388A1 (en) * 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antibodies Against ERBB3 and Uses Thereof
US8691225B2 (en) 2007-02-16 2014-04-08 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ErbB3 and uses thereof
US8961966B2 (en) 2007-02-16 2015-02-24 Merrimack Pharmaceuticals, Inc. Antibodies against ERBB3 and uses thereof
US9487588B2 (en) 2007-02-16 2016-11-08 Merrimack Pharmaceuticals, Inc. Antibodies against the ectodomain of ERBB3 and uses thereof
CN101674846A (zh) * 2007-02-16 2010-03-17 梅里麦克制药股份有限公司 ErbB3抗体及其用途
US7846440B2 (en) 2007-02-16 2010-12-07 Merrimack Pharmaceuticals, Inc. Antibodies against ErbB3 and uses thereof
WO2008100624A3 (en) * 2007-02-16 2009-01-15 Merrimack Pharmaceuticals Inc Antibodies against erbb3 and uses thereof
EP2716301A3 (en) * 2007-02-16 2014-07-16 Merrimack Pharmaceuticals, Inc. Antibodies against ERBB3 and uses thereof
EA020465B1 (ru) * 2007-02-16 2014-11-28 Мерримак Фармасьютикалз, Инк. ИЗОЛИРОВАННЫЕ МОНОКЛОНАЛЬНЫЕ АНТИТЕЛА, КОТОРЫЕ СВЯЗЫВАЮТСЯ С ErbB3, НАБОРЫ И КОМПОЗИЦИИ, ИХ СОДЕРЖАЩИЕ, И ИХ ПРИМЕНЕНИЕ
AU2008216600B2 (en) * 2007-02-16 2013-09-05 Merrimack Pharmaceuticals, Inc. Antibodies against ErbB3 and uses thereof
EP3248617A3 (en) * 2007-02-16 2018-02-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
WO2008100624A2 (en) 2007-02-16 2008-08-21 Merrimack Pharmaceuticals, Inc. Antibodies against erbb3 and uses thereof
CN101674846B (zh) * 2007-02-16 2014-07-02 梅里麦克制药股份有限公司 ErbB3抗体及其用途
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
WO2009156179A1 (en) * 2008-06-27 2009-12-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Her3 as a determinant for the prognosis of melanoma
US8623592B2 (en) 2008-08-15 2014-01-07 Merrimack Pharmaceuticals, Inc. Methods and systems for predicting response of cells to a therapeutic agent
US9518130B2 (en) 2010-03-11 2016-12-13 Merrimack Pharmaceuticals, Inc. Use of ERBB3 inhibitors in the treatment of triple negative and basal-like breast cancers
US8895001B2 (en) 2010-03-11 2014-11-25 Merrimack Pharmaceuticals, Inc. Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers
EP2611829A4 (en) * 2010-09-03 2014-05-07 Glaxosmithkline Ip Dev Ltd NOVEL ANTIGEN BINDING PROTEINS
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins
CN104011079B (zh) * 2011-11-09 2017-06-16 Uab研究基金会 Her3抗体及其用途
CN104011079A (zh) * 2011-11-09 2014-08-27 Uab研究基金会 Her3抗体及其用途
US9637543B2 (en) 2011-11-09 2017-05-02 The Uab Research Foundation HER3 antibodies and uses thereof
EP2788377A4 (en) * 2011-11-09 2015-11-18 Uab Research Foundation HER3 ANTIBODIES AND USES THEREOF
AU2012335543B2 (en) * 2011-11-09 2017-08-24 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
AU2012335543C1 (en) * 2011-11-09 2017-12-14 Beijing Cotimes Biotech Co., Ltd., HER3 antibodies and uses thereof
WO2013071058A1 (en) * 2011-11-09 2013-05-16 The Uab Research Foundation Her3 antibodies and uses thereof
US9688761B2 (en) 2013-12-27 2017-06-27 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
US10273304B2 (en) 2013-12-27 2019-04-30 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with ERBB3 inhibitors and/or chemotherapies
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors

Also Published As

Publication number Publication date
CA2456723A1 (en) 2003-02-20
CN1541109A (zh) 2004-10-27
AU2002333384B2 (en) 2007-11-15
CN102078613A (zh) 2011-06-01
PT1414494E (pt) 2009-06-12
CY1110322T1 (el) 2015-01-14
JP5226926B2 (ja) 2013-07-03
US9011851B2 (en) 2015-04-21
ATE424219T1 (de) 2009-03-15
DE60231407D1 (de) 2009-04-16
DK1414494T3 (da) 2009-07-06
CN1541109B (zh) 2013-07-10
US20040197332A1 (en) 2004-10-07
EP1414494B1 (en) 2009-03-04
ES2323772T3 (es) 2009-07-24
EP1414494A1 (en) 2004-05-06
CA2456723C (en) 2016-02-09
WO2003013602A1 (en) 2003-02-20
EP2067792A2 (en) 2009-06-10
JP2005504044A (ja) 2005-02-10

Similar Documents

Publication Publication Date Title
EP1283053A1 (en) Inhibitors of HER3 activity
AU2002333384A1 (en) Inhibitors of HER3 activity
JP7358256B2 (ja) 医薬組成物
EP1889631B1 (en) Cell growth inhibition
US9505843B2 (en) Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same
KR101748707B1 (ko) ｃ-Ｍｅｔ에 특이적으로 결합하는 항체 및 그를 이용한 암 진단용 키트
WO2015016559A1 (en) Anti-egfr antibody and anti-c-met/anti-egfr bispecific antibodies comprising the same
US20200291130A1 (en) Antibodies for the treatment of erbb-2/erbb-3 positive tumors
KR20230125774A (ko) 항-cd73 항체 및 이의 용도
WO2024158047A1 (ja) 抗ｌｒｒｃ１５抗体
US10000569B2 (en) Anti-cMet/anti-EGFR/anti-HER3 multispecific antibodies and use thereof
KR20240049339A (ko) Egfr 및 her3를 표적으로 하는 이중특이적 4가 항체
KR102575994B1 (ko) 항-tm4sf4 항체 및 이의 용도
CN113728010A (zh) 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
CN111201244A (zh) 特异性结合到水通道蛋白3(aqp3)的细胞外域的抗aqp3单克隆抗体及其用途
AU2008200654B2 (en) Inhibitors of HER3 activity
EP4635985A1 (en) Anti-tm4sf4 humanized antibodies and use thereof
US20240299518A1 (en) Method for the treatment of patients with carcinomas
RU2831836C2 (ru) Биспецифическое антитело анти-egfr/анти-4-1вв и его применение
EP4357363A1 (en) Anti-tm4sf4 humanized antibody and use thereof
WO2025117871A1 (en) Bispecific tetravalent antibody targeting her2 and her3
CN119451982A (zh) 结合her-3和her-2或egfr的双特异性抗体
Nadri et al. Production and characterization of monoclonal antibodies against the dimerization domain of human HER2
MXPA98007723A (en) Erbb3 antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

AKX Designation fees paid
REG Reference to a national code

Ref country code: DE

Ref legal event code: 8566

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030813